Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events

Cristina Gervasoni, Paola Meraviglia, Simona Landonio, Sara Baldelli, Serena Fucile, Laura Castagnoli, Emilio Clementi, Agostino Riva, Massimo Galli, Giuliano Rizzardini, Dario Cattaneo

Research output: Contribution to journalArticle

Abstract

Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated with these drug-related adverse events are poorly characterized. Our objective was to investigate such factors in patients treated long term with daily tenofovir. One-hundred Caucasian HIV-positive patients with basal creatinine clearance >80 mL/min treated with tenofovir for at least 6 months and with at least one assessment of tenofovir plasma trough concentrations were considered. Tenofovir-associated adverse events were defined as the appearance of pathological proteinuria, worsening of renal function or bone demineralization. By multivariate regression analysis, we found that serum creatinine (p = 0.003) and body weight (p = 0.002) were the factors independently associated with plasma tenofovir concentrations. In particular, women with body weight50 Kg (160±93 vs.71±52 ng/mL, p

Original languageEnglish
Article numbere80242
JournalPLoS One
Volume8
Issue number12
DOIs
Publication statusPublished - Dec 2 2013

    Fingerprint

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Gervasoni, C., Meraviglia, P., Landonio, S., Baldelli, S., Fucile, S., Castagnoli, L., Clementi, E., Riva, A., Galli, M., Rizzardini, G., & Cattaneo, D. (2013). Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. PLoS One, 8(12), [e80242]. https://doi.org/10.1371/journal.pone.0080242